Author Interviews, Johns Hopkins, NEJM, Pulmonary Disease / 11.09.2013
COPD: Comparing Tiotropium Delivery Devices
MedicalResearch.com Interview with:
Dr. Robert A. Wise MD
Professor of Medicine Johns Hopkins University School of Medicine
5501 Hopkins Bayview Circle
Baltimore, MD 21224
MedicalResearch.com: What are the main findings of the study?
Dr. Wise: The TIOSPIR trial was a landmark study, one of the largest ever conducted for chronic obstructive pulmonary disease (COPD). It was designed to test the comparative safety and effectiveness of two delivery devices of tiotropium, a long-acting bronchodilator. One formulation is the Respimat multi-dose soft mist inhaler and the other formulation is the single dose HandiHaler dry powder inhaler.
After following more than 17000 patients for an average of 2.3 years, TIOSPIR showed that there was no difference in either the safety in terms of mortality or adverse cardiovascular events between the two devices. Moreover, both devices showed similar effectiveness in terms of time to first COPD exacerbation.
A lung function substudy in 1370 patients showed that the 5 microgram dose of Respimat was equivalent to the HandiHaler as a bronchodilator, but the 2.5 microgram dose was not quite as effective.
















